What Is Survodutide?
Survodutide is a once-weekly injectable GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. Like mazdutide and the glucagon-targeting component of retatrutide, it combines GLP-1's appetite suppression with glucagon's fat-burning and energy expenditure effects.
The MASH Opportunity
One of the most significant aspects of survodutide's pipeline is its investigation for metabolic-associated steatohepatitis (MASH), previously known as NASH. MASH is a progressive liver disease closely linked to obesity and metabolic syndrome, with very limited treatment options. Survodutide's combination of fat-burning (via glucagon) and metabolic improvement (via GLP-1) creates a plausible mechanism for liver benefit beyond what weight loss alone provides.
Phase 2 and Phase 3 Results
Phase 2 results published in 2024 showed survodutide producing meaningful weight loss with an acceptable safety profile, sufficient to support advancement into Phase 3 trials for both obesity and MASH. The pivotal Phase 3 SYNCHRONIZE-1 trial has now completed, reporting 16.6% average weight loss at 76 weeks with the higher dose — versus 3.2% with placebo. A pre-specified sub-study analysis showed survodutide also reduced visceral fat by up to 34% relative to baseline, a finding that distinguishes it from some competitors where visceral fat reduction data is less granular.
Current Status (Updated August 2026)
SYNCHRONIZE-1 — the pivotal Phase 3 obesity trial — has completed and met its primary endpoints, showing 16.6% weight loss at 76 weeks with the higher dose. Boehringer Ingelheim has not yet submitted an NDA to the FDA; the company is reviewing SYNCHRONIZE-1 data alongside results from additional Phase 3 sub-studies expected later in 2026. The MASH indication remains in active trials. If approved, survodutide would be notable as a treatment targeting both obesity and metabolic liver disease with a single once-weekly injection.
August 2026 Update: SYNCHRONIZE-1 Phase 3 Complete
Phase 3 SYNCHRONIZE-1 Results Confirmed: Boehringer Ingelheim has published detailed data from the completed SYNCHRONIZE-1 Phase 3 trial. Survodutide at the higher dose achieved 16.6% average weight loss at 76 weeks vs. 3.2% with placebo — meeting primary endpoints. A pre-specified sub-study showed an even more notable finding: a 34% reduction in visceral fat relative to baseline, which is a differentiating result given the link between visceral adiposity and cardiometabolic disease. The MASH indication remains one of the most watched — resmetirom (Rezdiffra) became the first FDA-approved MASH drug in 2024, but its mechanism leaves room for GLP-1/glucagon-based approaches that combine weight loss with direct liver effects. Boehringer Ingelheim/Zealand Pharma have not yet announced a PDUFA target; additional Phase 3 data readouts are expected through 2026 before NDA submission, with FDA submission currently estimated for 2027 at the earliest.